Physician profile
Alejandro Pino
NPI 1457748089
$8,349.62
in general payments reported to CMS, 2019-2025
24 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $1,418 · 2023: $1,926 · 2024: $2,532 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,922 · Education: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,922.23 |
| Education | $520.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,177.64 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $961.74 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $787.58 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $652.06 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $651.38 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $624.65 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $513.80 | 2023-2025 | Dupixent |
| Ethicon INC. | $488.24 | 2021 | |
| Stryker Corporation | $218.07 | 2023-2024 | N/A, Claw II |
| Sanofi-Aventis U.S. LLC | $215.46 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $187.20 | 2023-2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $164.49 | 2023-2025 | Acthar |
| Insmed, INC. | $157.28 | 2024-2025 | Arikayce |
| Grifols USA, LLC | $157.23 | 2022-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $69.93 | 2025 | Yupelri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $59.84 | 2024-2025 | (O58) Sleep Respiratory Care Und, Encore |
| Abbvie INC. | $55.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.97 | 2023 | Glassia |
| Verona Pharma, INC. | $46.46 | 2025 | Ohtuvayre |
| Baxter Healthcare | $28.32 | 2023 | Hillrom - Life 2000 Ventilation System |
| Optinose US, INC. | $25.01 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.87 | 2024 | |
| Pulmonx Corporation | $20.18 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Electromed, INC. | $15.28 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Pino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.